Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents

Abstract

Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out as a major determinant of efficacy when RT and CDK4/6 inhibitors are combined for breast cancer therapy.

Keywords

• 4t1 cells
• immune checkpoint inhibitors
• mcf7 cells
• mpa/dmba-driven mammary carcinomas
• targeted anticancer agents
• ts/a cells